CTOs on the Move

Vitae Pharmaceuticals

www.vitaepharma.com

 
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Vitae Pharmaceuticals raised $35M on 03/25/2016

Similar Companies

Bedrocan

Bedrocan is an experienced producer of pharmaceutical-grade medicinal cannabis with over 13 years growing expertise in global markets. We provide patients and healthcare professionals with safe, effective and consistent medicine for the appropriate management of diagnosed health conditions. Our strains of pharmaceutical-grade cannabis are used by thousands of patients in seven countries, including Canada. We provide three fully standardized products, and as a result, our standardized strains are the choice for researchers and academics who study the medical effects of cannabis.

Remel Inc

Remel Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intracel Resources

Intracel Resources is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Joule Unlimited

Joule has pioneered a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Free of feedstock constraints and complex processing, this platform can achieve unrivaled scalability, volumes and costs without the use of any agricultural land, fresh water or crops. Unlike products derived with complexity from petroleum or biomass, Joule Sunflow® products are produced in a direct, continuous process from abundant resources. The novel CO2-to-liquids conversion requires only sunlight, non-potable water and engineered bacteria that function as living catalysts to produce specific products, including ethanol and hydrocarbon fuels that are inherently compatible with existing infrastructure. Joule’s highly efficient process and production system are well suited for deployment around the world, unhindered by land or resource constraints. This uniquely modular system can achieve replicable productivity, whether installed across 100 or 1,000 acres, mitigating scale-up risks and ensuring stability of supply. At full-scale commercialization in ideal locations, the company ultimately targets 25,000 US gallons of Joule Sunflow®-E (solar ethanol) or 15,000 US gallons of Joule Sunflow®-D (solar diesel) per acre annually, for approximately $1.20/US gallon ($50/barrel). Joule has successfully pilot-tested its platform for over two years, initiated demonstration-scale operations, and assembled a specialized team to lay the groundwork for commercial deployment. The company is moving rapidly to commercialize Joule Sunflow-E, with Joule Sunflow-D and additional hydrocarbon fuels to follow. Joule is privately held and has raised approximately $200 million in funding to date. The company was founded within Flagship VentureLabs™, and operates out of Bedford, Massachusetts and The Hague, The Netherlands, with production operations in Hobbs, New Mexico.

Biosplice Therapeutics

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.